
Renal Cell Carcinoma
Latest News

Phase 3 ZIRCON Study Shows High Sensitivity/Specificity With 89Zr-DFO-girentuximab in ccRCC
Latest Videos

CME Content
More News

During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable discussion, Chandler Park, MD, discussed the trials that led to the approval of frontline combination regimens for patients with advanced clear cell renal cell carcinoma.

In an interview with Targeted Oncology, Kathryn Beckermann, MD, PhD, discussed her talk from the International Kidney Cancer Symposium: North America 2022 on risk stratifications and considerations for improving outcomes for patients with renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.

Matthew T. Campbell, MD, discusses survival outcomes for patients with both metastatic renal cell carcinoma and sarcomatoid dedifferentiation and how they each have evolved over the past few years.

During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.

Benjamin Garmezy, MD, discusses the choice of third-line therapies in patients with advanced renal cell carcinoma.

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Ulka N. Vaishampayan, MBBS, discussed the frontline combination regimens available for a patient with favorable risk clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.

Naomi B. Haas, MD, discusses the choice of frontline treatment for favorable-risk patients with advanced clear cell renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Saby George, MD, and participants discussed the role of tivozanib and other later-line options in patients with advanced renal cell carcinoma.

Findings from phase 3 adjuvant immuno-oncology trials in renal cell carcinoma have demonstrated some benefit in disease-free survival, but questions about overall survival remain.

During a Targeted Oncology case-based roundtable event, Saby George, MD, discussed which second-line therapy would be appropriate for a patient who discontinued frontline immunotherapy/tyrosine kinase inhibitor therapy due to immune-related toxicity.

During a Targeted Oncology case-based roundtable event, Rana McKay, MD, and participants discussed the case of a patient with previously untreated advanced renal cell carcinoma with favorable risk status.

Nizar M. Tannir, MD, discussed the case of a 59-year-old Black woman with clear cell renal cell carcinoma during a live event.

Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.

Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.

Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.

Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.

































